Patenting the Microbiome: trends, Challenges and Insights

Sabatelli, Anthony D; Vincent, Nicholas G.; Puleo, D.E.

doi:10.4155/ppa-2017-0028

Cited by 4 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Investment in microbiome research can be hampered by a lack of intellectual property and limited patent protection. For example, patent law does not allow natural materials or living organisms to be patented [39].…”

Section: Development and Commercialization Challengesmentioning

confidence: 99%

Current Regulation and Initial Considerations for Successful Development and Commercialization of Microbiome Therapies

Thanush,

Basavaraj,

Gowrav

2023

Advanced Gut & Microbiome Research

View full text Add to dashboard Cite

The gut microbiome is frequently referred to as the “second brain” or “second genome,” referring to the impact of the gut microbiota on our health. The microbiome is formed at birth, grows with the host, and is impacted by environmental variables such as nutrition, antibiotics, and lifestyle. Understanding the host health-gut microbiota correlation opens the possibility of modifying the gut microbiome to manage an individual’s health. Several techniques, such as probiotic, prebiotic, synbiotic, and faecal microbiota transplantation (FMT), are explored to alleviate the dysbiosis-related negative consequences and restore the gut microbiota in humans. While microbiome-based medicines have made remarkable progress in the last decade, from prebiotics and probiotics to live biotherapeutics, there are still safety concerns and regulatory issues to be addressed. The FMT treatment is currently experimental and lacks authorization, posing numerous ethical, legal, and social challenges that must be resolved as part of an effective regulatory policy response. This study gives an outline of our current understanding of microbiome restoration approaches as well as safety concerns regarding how these approaches are regulated. It presents an outline of the contemporary gut microbiome therapeutic development landscape and an assessment of the commercialization hurdles encountered.

show abstract

Section: Development and Commercialization Challengesmentioning

confidence: 99%

Current Regulation and Initial Considerations for Successful Development and Commercialization of Microbiome Therapies

Thanush,

Basavaraj,

Gowrav

2023

Advanced Gut & Microbiome Research

View full text Add to dashboard Cite

show abstract

“…While others have previously taken biased approaches to characterize the microbiome patent space in terms of classifying patent families into certain commercial areas or disease indications (Consultancy, 2016; Sun et al, 2016; Sabatelli et al, 2017), we focused on an unbiased approach to assess quality parameters. Our in-depth patent analysis using PatentSight revealed that a diverse mix of top patent owners from large industry, startups and academia are holding some of the key patent assets (Figure 2).…”

Section: Academia and Startups Capture Some Of The Most Valuable Portmentioning

confidence: 99%

Patents as Early Indicators of Technology and Investment Trends: Analyzing the Microbiome Space as a Case Study

Fankhauser¹,

Moser

Nyfeler

2018

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

The human microbiome is the collective of microbes living in symbiosis on and within humans. Modulating its composition and function has become an attractive means for the prevention and treatment of a variety of diseases including cancer. Since the initiation of the human microbiome project in 2007, the number of academic publications and active patent families around the microbiome has grown exponentially. Screening patent databases can be useful for the early detection and the tracking of new technology trends. However, it is not sufficient to assess portfolio sizes because emerging players with small but high-quality patent portfolios will be missed within the noise of large but low-quality portfolio owners. Here we used the consolidated database and software tool PatentSight to benchmark patent portfolios, and to analyze key patent owners and innovators in the microbiome space. Our study shows how in-depth patent analyses combining qualitative and quantitative parameters can identify actionable early indicators of technology and investment trends from large patent datasets.

show abstract